TLPH · Talphera, Inc.

Revenue fell to $0 from $27K in the prior-year quarter, a 100% decline, as efforts to sell remaining DSUVIA inventory held by Alora to the DoD yielded no orders. Management notes continued facilitation attempts but anticipates destruction of unsold inventory if no purchases materialize, effectively closing out this discontinued product line. This revenue drought underscores Talphera's transition from legacy assets to its pipeline focus, with no immediate topline replacement until potential nafamostat milestones like NEPHRO CRRT data, emphasizing the pre-revenue biotech profile reliant on development progress.

Operating loss expanded 35% to -$3.9M from -$2.9M, driven by the company's operating plan centered on nafamostat product candidates' development and supply activities. These investments reflect strategic prioritization of pipeline advancement amid the absence of product sales, consistent with Talphera's history of losses since inception and expectation of continued operating deficits to support planned operations.